NexPoint Real Estate Finance (NREF) investor relations material

Executive summary

• Net income attributable to common stockholders was $5.4 million, or $0.29 per diluted share, for Q2 2026, down from $0.54 in Q2 2025 and $0.42 in Q1 2026.

• Earnings available for distribution (EAD) per diluted share rose to $0.46, and cash available for distribution (CAD) per diluted share was $0.58, with the dividend of $0.50 per share covered 1.16x by CAD.

• Portfolio reached $1.1 billion across 85 investments, with significant allocations to life sciences (39.4%) and multifamily (37.6%).

• Closed a $375 million term loan facility, repaid $180 million in senior unsecured notes, and raised $22.6 million via Series C preferred, enhancing capital flexibility.

• Portfolio focused on life sciences, self-storage, multifamily, and industrial sectors for structural, cycle-resistant demand.

Financial highlights

• Book value per diluted share decreased 1.9% sequentially to $18.60 as of June 30, 2026, mainly due to unrealized losses.

• Debt outstanding was $836.6 million with a weighted average cost of 6.3% and average maturity of 2.6 years.

• Debt to equity ratio stood at 0.88x, with secured debt collateralized by $1.4 billion in assets.

• Net interest income increased to $16.5 million for Q2 2026.

• Dividends declared per common share were $0.50 for Q2 and $1.00 for the first half, unchanged year-over-year.

Outlook and guidance

• Q3 2026 guidance: EAD expected at $0.433–$0.435 per diluted share; CAD at $0.553–$0.555 per share; net income guidance is $7.4M–$9.8M.

• Q3 2026 dividend of $0.50 per common share announced.

• Management expects sufficient funds for operations and obligations over the next twelve months.

• Residential fundamentals are improving, with blended lease trade outs turning positive in July for the first time since early 2025.

• Anticipates redeploying capital from Alewife life science asset into residential assets as refinancing progresses.